文献速递炎症性肠病

高体重指数与儿童克罗恩病对抗肿瘤坏死因子治疗的反应

High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2024-03-06

本研究为COMBINE试验的二次分析,比较正常与高体重指数(BMI)的儿童克罗恩病(PCD)患者对抗肿瘤坏死因子(anti-TNF)治疗的反应及药物水平。224例参与者中,高BMI与阿达木单抗(ADA)治疗失败相关(7/10 [70%] vs 12/52 [23%],HR 0.29,P=0.007),且高BMI者ADA中位谷浓度较低(5.8 vs 12.8 μg/mL,P=0.02);英夫利西单抗(IFX)组无此差异。

要点

  • 高BMI与ADA治疗失败风险升高相关(7/10 [70%] vs 12/52 [23%],HR 0.29,P=0.007)。
  • 高BMI的ADA治疗患者中位谷浓度低于正常BMI者(5.8 vs 12.8 μg/mL,P=0.02)。
  • IFX治疗组中,BMI分组间临床结局及药物谷浓度无差异。

核心结论

  • 超重和肥胖的儿童克罗恩病患者较正常BMI者更易出现ADA治疗失败。
  • 较高BMI与较低药物谷浓度相关。
  • 标准ADA剂量可能对超重儿童克罗恩病患者不足。
  • IFX治疗组中未观察到临床结局或药物水平的差异,可能源于按体重给药和/或更多使用主动药物监测。

研究设计与样本

  • COMBINE试验的二次分析,比较正常BMI与BMI Z评分>1的儿童克罗恩病患者至治疗失败时间。
  • 共纳入224例参与者,其中IFX起始者162例,ADA起始者62例。
  • 正常BMI者111例(81%),高BMI者43例(19%)。
  • 分析中调整了处方抗TNF药物(IFX或ADA)、试验治疗分配(联合治疗或单药治疗)及相关协变量。

主要发现

  • ADA起始者中,高BMI与治疗失败相关(7/10 [70%] vs 12/52 [23%],HR 0.29,P=0.007)。
  • IFX起始者中,高BMI与治疗失败无关。
  • ADA治疗的高BMI患者中位ADA水平低于正常BMI者(5.8 vs 12.8 μg/mL,P=0.02)。
  • IFX谷浓度在BMI组间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI). METHODS: The COMBINE trial compared anti-TNF monotherapy with combination therapy with methotrexate in patients with PCD. In this secondary analysis, a comparison of time-to-treatment failure among patients with normal BMI vs BMI Z -score >1, adjusting for prescribed anti-TNF (infliximab [IFX] or adalimumab [ADA]), trial treatment assignment (combination vs monotherapy), and relevant covariates. Median anti-TNF levels across BMI category was also examined. RESULTS: Of 224 participants (162 IFX initiators and 62 ADA initiators), 111 (81%) had a normal BMI and 43 (19%) had a high BMI. High BMI was associated with treatment failure among ADA initiators (7/10 [70%] vs 12/52 [23%], hazard ratio 0.29, P = 0.007) but not IFX initiators. In addition, ADA-treated patients with a high BMI had lower ADA levels compared with those with normal BMI (median 5.8 vs 12.8 μg/mL, P = 0.02). IFX trough levels did not differ between BMI groups. DISCUSSION: Overweight and obese patients with PCD are more likely to experience ADA treatment failure than those with normal BMI. Higher BMI was associated with lower drug trough levels. Standard ADA dosing may be insufficient for overweight children with PCD. Among IFX initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ebach DR, Jester TW, Galanko JA, et al. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. Am J Gastroenterol. 2024. PMID: 38445644. doi:10.14309/ajg.0000000000002741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。